YHLO Launches New SARS-CoV-2 Neutralization Antibody (NAb) Assay

By LabMedica International staff writers
Posted on 03 Mar 2021
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has launched its new SARS-CoV-2 NAb test kit designed to detect all antibodies that are able to inhibit the binding between S1 RBD and ACE2 in both CLIA and FIA platforms.

The test is intended to be used for the evaluation of neutralization antibodies in discharged patients, monitor neutralization antibodies in people who had COVID-19 vaccination, and the efficacy of immunotherapy. Neutralization antibody assay is essential for many vaccines and treatments for other infectious diseases, e.g. Anti-HBs assay is measuring neutralization antibody of Hepatitis B Virus. By definition, neutralization antibodies against SARS-CoV-2 can stop COVID-19 Receptor Binding Domain (RBD) from binding to Angiotensin-Converting Enzyme 2 (ACE2) receptor in human cells, which prevent SARS-CoV-2 to invade human cells.

Illustration

When compared to traditional PRNT and ELISA test, YHLO’s SARS-CoV-2 NAb test kit offers the distinct advantage of being a quantitative test on the CLIA/FIA platform, which provides valuable clinical data to any studies that intend to assess either immune response or therapy efficacy in COVID-19. Additionally, the use of the CLIA/FIA method drastically improves testing capacity and efficiency, aiding the large-scale study on NAb.

Some additional advantages offered by YHLO’s SARS-CoV-2 NAb test kit include quantitative test yielding data with medical value, high throughput with short TAT (first result <30 minutes), full automation which minimizes human-induced error, cost-effectiveness and lower labor intensity, and a dynamic design that mimics the human body internal environment.




Latest COVID-19 News